Health ❯ Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials Obesity Treatments Monoclonal Antibodies Alzheimer's Disease Combination Therapy Eli Lilly Novo Nordisk Immunotherapy Oncology GLP-1 Drugs

3 ARTICLES

4d ago

EU Advisers Back Susvimo Implant as New Option for Wet Age‑Related Macular Degeneration

A European Commission decision and publication of official prescribing information are required before the refillable ranibizumab implant can be used by trained vitreoretinal surgeons.

3 ARTICLES

5d ago

FDA Grants Priority Review to Pfizer’s Talzenna Plus Xtandi for HRR-Altered mCSPC

9 ARTICLES

last wk.

Viking Therapeutics Rallies as Weight‑Loss Program Moves Toward Late‑Stage Testing

8 ARTICLES

3w ago

FDA Scientists Say Evidence Lacks for Allowing Seven Popular Peptides in Compounding

3 ARTICLES

4w ago

Drug Development

EU Advisers Back Susvimo Implant as New Option for Wet Age‑Related Macular Degeneration

FDA Grants Priority Review to Pfizer’s Talzenna Plus Xtandi for HRR-Altered mCSPC

Novartis Returns to Sales Growth as New Drugs Offset Entresto Slump

FDA Approves First Oral PCSK9 Pill, Merck’s Lipfendra

Donanemab Slows Alzheimer's Decline, New AAIC Data Show

WashU Team Uses In‑Body Click Chemistry to Assemble Dual‑Target Cancer Drugs

Johnson & Johnson Beats Q2 Estimates and Lifts Full‑Year Outlook

Chai Discovery Raises $400 Million to Scale AI Drug Design

Biogen's Tau Drug Cuts Brain Tau but Misses Dose‑Response Goal

FDA Approves At‑Home Weekly Subcutaneous Starter Dose for Leqembi

Never miss stories about

Drug Development

Late‑Stage Trial of Wainua Misses Primary Goal in ATTR‑CM Study

Silo Pharma Raises $4 Million in Private Placement as Shares Fall 28%

FDA Clears Wearable Injector Form of Sanofi’s Multiple Myeloma Drug

Ipsen Says Dysport Met Phase 3 Endpoints for Episodic and Chronic Migraine

EMA Opens Rolling Review as U.S. Hospitals Start Early Access to Daraxonrasib

Vertex to Buy Crinetics for $10 Billion, Gaining Oral Endocrine Drugs

Healthcare ETFs Force a Choice Between Low Cost and Higher Growth

Viking Therapeutics Rallies as Weight‑Loss Program Moves Toward Late‑Stage Testing

FDA Scientists Say Evidence Lacks for Allowing Seven Popular Peptides in Compounding

FDA Grants Priority Review to Roche’s Enspryng for Thyroid Eye Disease

Never miss stories about

Drug Development